线粒体局部化素17促进基底性胰腺癌的化学抵抗
Chun-Hao Pan1, Yinghuan Lyu2, Monisankar Ghosh2
1Memorial Sloan Kettering Cancer Center New York, NY United States.
Cancer research
|March 12, 2026
概括
基本类胰腺癌依赖于线粒体素17 (K17) 来合成胺素. 抑制K17s线粒体进入或DHODH酶可以提高化疗的有效性,改善这种侵袭性癌症亚型的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢途径 代谢途径
背景情况:
- 基本类胰腺管腺癌 (PDAC) 由于其致死性和对治疗的耐药性, presents一个重要的临床挑战.
- 氨酸17 (K17) 的上调与基底类PDAC的预后不佳相关,这表明它在瘤攻击性方面的潜在作用.
研究的目的:
- 阐明驱动基底类PDAC的分子机制.
- 确定K17表达PDAC中的治疗漏洞.
主要方法:
- 通过细胞系和动物模型,研究了K17在新皮里米丁生物合成中的作用.
- 利用线粒体局部化序列 (MLS) 和TOM20相互作用研究.
- 评估了K17抑制和DHODH阻断对宝石胺敏感性的影响.
主要成果:
- 在基底类PDAC中确定了内线粒体K17作为de novo pyrimidine生物合成的必需物.
- 通过防止其降解,K17稳定了二甲酸脱酶 (DHODH).
- 抑制K17线粒体进口或DHODH药理学阻塞使PDAC细胞对gemcitabine敏感.
- 在K17+ PDAC小鼠模型中,联合DHODH抑制和gemcitabine治疗显著降低了瘤生长和改善了生存率.
结论:
- 在基底类的PDAC中,K17在维持金字素生物合成方面发挥着关键的线粒体作用.
- 针对K17介导的代谢途径,特别是DHODH,代表了对K17+PDAC的有前途的治疗策略,提高了标准化疗的疗效.
更多相关视频
相关概念视频
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...